Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALE.P03 in Advanced or Metastatic CLDN1+ Solid Tumors
NCT07169734Phase 2Recruiting
- Sponsor
- Alentis Therapeutics
- Start
- Aug 2025
- Primary completion
- Apr 2029
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 8
01
Overview
A Phase 2 trial of ALE.P03 in cervical squamous cell carcinoma (CSCC), non-small cell lung cancer, squamous cell carcinoma (NSCLC), colorectal cancer (CRC), intrahepatic cholangiocarcinoma (ICC), urothelial carcinoma (UC), sponsored by Alentis Therapeutics. Started Aug 2025; status: recruiting.
02
Drugs
ALE.P03
03
Conditions
cervical squamous cell carcinoma (CSCC)non-small cell lung cancer, squamous cell carcinoma (NSCLC)colorectal cancer (CRC)intrahepatic cholangiocarcinoma (ICC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07169734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07169734.